3 6 Ke·2025-11-05 10:52Core Insights - A-share listed companies in China have seen a continuous increase in R&D investment, reaching a total of 1.16 trillion yuan in the first three quarters of 2025, marking a year-on-year growth of 3.88% [1][2] - High R&D investment is becoming a significant driver for performance growth among listed companies, particularly in sectors like biomedicine, semiconductors, and artificial intelligence [1][4] R&D Investment Overview - In the first three quarters of 2025, 168 companies invested over 1 billion yuan in R&D, with 13 companies exceeding 10 billion yuan [2] - BYD leads with R&D expenses of 43.748 billion yuan, followed by China State Construction and China Mobile with 23.979 billion yuan and 20.423 billion yuan respectively [2][3] Sector-Specific Insights - Companies with high R&D investment are primarily in biomedicine, semiconductors, and AI, which are crucial for building technological barriers and driving industry innovation [1][10] - China State Construction is advancing digital innovation and smart construction technologies, while China Mobile has established the world's first 6G small-scale test network [4] Notable Companies - ZTE Corporation reported R&D expenses of 17.814 billion yuan, accounting for 17.72% of its revenue, focusing on AI-related product development [4] - CATL's R&D expenses reached 15.068 billion yuan, with a year-on-year growth of 15.26%, highlighting its innovation in battery technology [5] R&D Intensity by Market Segment - The overall R&D intensity in the A-share market is 2.16%, with the Sci-Tech Innovation Board showing a significantly higher intensity of 11.22% [6] - The median R&D intensity for companies on the Sci-Tech Innovation Board is 12.4%, indicating a strong focus on technology [6][7] Industry Trends - The computer, biomedicine, and electronics sectors exhibit high R&D intensity, with 43 companies in computing, 25 in biomedicine, and 15 in electronics among the top 100 for R&D investment [8] - The differences in R&D investment ratios among A-share companies reflect industry characteristics and corporate strategies, with biomedicine and semiconductors requiring higher investment due to long development cycles and international competition [10]